ICON Plc

ICON’s near-term, long-term and #netzero targets have been validated by #SBTi. In 2024 we decreased Scope 3 emissions 7.56% compared to 2022. Read more: ow.ly/viYB50VZTWN

EU HTAR’s first year is complete and 2026 is set to scale fast. - ~50 JCAs expected - High risk medical devices enter scope - PICO complexity remains a key challenge Read the full breakdown: ow.ly/WMOp50Yv8lo #EUHTA #HTAR #JCA #RegulatoryAffairs #MarketAccess

The future of #MultipleSclerosis care is shifting—from relapse suppression to progression focused insight. New ICD 10 subtype codes and real world evidence are unlocking more precise MS research. Read more: ow.ly/h8nl50YvOkE

ICON’s long Nguyen will join the upcoming Bioanalysis Zone panel. Join the discussion as we explore challenges like instrument variability, outsourcing complexities, and the future of automation, imaging flow cytometry, and cloud‑based collaboration. ow.ly/1Vte50YsNrj

Long‑acting injectables have reshaped HIV treatment, but they still can’t overcome the limits of ART. Our latest article explores next‑generation approaches that may move us closer to durable immunity. ow.ly/o17y50YuCxn

#Biosimilars developers will need to rethink their approach to stay competitive in the coming years. Learn how regulatory shifts, advances in modality, the competitive landscape and other factors impact biosimilar strategy in the whitepaper. Download: ow.ly/WUOR50YsIUx

On 25 March at 03:00 PM, Dr. Anne Behringer will present virtually at #DIAEurope where she will discuss “Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality”. Explore more. ow.ly/Qo4650XWz0x

ICON’s experts examine the challenges of ADC development and why early scientific advice, dose optimisation and accelerated designations are vital for efficient approval. ow.ly/oPVf50YnYEX #DrugDevelopment #RegAffairs #ProjectOptimus #OncologyResearch

ICON’s 2025 China biotech survey report highlights the impact of accelerated approval timelines on innovation and global partnerships. Regulatory review timelines shortened from 60 to 30 days in 2025. Explore how reform is enabling faster market entry: ow.ly/17Bk50YiEzz

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Read the full blog to see how bile sampling is reshaping human ADME and unlocking deeper understanding of drug behaviour. ow.ly/UKhg50YmiB4

Meet the @ICONplc team 30 March - 2 April at #WVCDC, booth 222 to learn how we have been supporting our clients’ vaccine development for a wide range of highly contagious and dangerous infectious diseases. ow.ly/rN5t50Yr92h

From advocacy to accelerated action. Watch our recent webinar on patient led drug development for ultra rare diseases. Recording now available: ow.ly/lV9E50YrHp8

In our latest article, we break down how smart formulation strategies, thoughtful placebo design, and right‑sized stability testing help accelerate early development while safeguarding study integrity. ow.ly/9pBG50YhZFm

Visit us at #ADPD2026, booth #29 to learn how our decentralised clinical trial solutions are focused on delivering data quicker to gain market access and reimbursement faster. ow.ly/w52Q50Y8FaE

Despite funding challenges, optimism prevails. ICON’s 2025 Global biotech survey report shows sustained confidence in investment delivery and product success. 92% confident in meeting milestones 91% expect product success Learn what drives this confidence: ow.ly/tXyG50YiEHl

83% of biotech leaders in China plan to increase R&D spending in the next 1–2 years. China’s biotech sector continues to expand, with accelerated regulatory timelines and growing collaboration shaping R&D strategy. Explore more: ow.ly/fFGM50Yraca

ADCs are gaining momentum globally, but varied regulatory expectations make strategy essential. ICON outlines key considerations, from agency engagement to pathways like SAKIGAKE and Project Orbis. ow.ly/oPVf50YnYEX #ADC #Oncology #RegulatoryStrategy #Biopharma

Digitised protocols and agentic AI are accelerating study workflows and bringing earlier insights to teams. The future of clinical data science is intelligent and human focused. Read more: ow.ly/f6am50Yse13

Join ICON’s Dr. Anne Behringer at #DIAEurope on 25 March, 03:00 PM for a virtual presentation on ‘Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality’. Learn more ow.ly/eu2g50XWyYm

How to navigate EU MAA Regulations and Registration. Download your copy today and get set for success ow.ly/ybaT50Xz22A #regulatoryaffair #EUCTR #EUClinicalTrialRegulation #europeanmedicinesagency #NMPA #biotech

Join the thousands of subscribers to our free newsletter and keep your knowledge of the latest clinical trial regulatory updates current: ow.ly/fznZ50YlPYi #regulatoryintelligence #regulatorycompliance #regintel #medicaldevices #biotech #pharma #FDA